SCHEMBL20600784

SCHEMBL20600784

Nc1nc(-c2ccc3ncsc3c2)c(-c2cc(F)c3ncccc3c2)n2ccnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 5/20 0.42
ADORA2A P29274 2/20 0.41
ADORA1 P30542 2/20 0.41
ADORA2B P29275 1/20 0.41
RIPK1 Q13546 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
VRK1 Q99986 1/20 0.39
DYRK1A Q13627 1/20 0.38
GLO1 Q04760 1/20 0.37
GRIA1 P42261 2/20 0.36
PDE4B Q07343 1/20 0.36
PDE4D Q08499 1/20 0.36
MAPK14 Q16539 1/20 0.36
KDM1A O60341 1/20 0.34
KLK7 P49862 1/20 0.34
APP P05067 1/20 0.34
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CSNK1E P49674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600733 0.86 KLK7 (0.46) TGFBR1ADORA2AADORA1ADORA3GRIA1
SCHEMBL20600461 0.85 GRIA1 (0.49) ADORA2AADORA1ADORA3GRIA1CCNT1
SCHEMBL20600762 0.84 DYRK1A (0.50) TGFBR1ADORA2AADORA1ADORA2BRIPK1
SCHEMBL20600680 0.84 ADORA2A (0.43) ADORA2AADORA1ADORA3GRIA1KLK7
SCHEMBL20600505 0.83 KDM1A (0.44) ADORA2AADORA1ADORA3GRIA1KDM1A
SCHEMBL20600432 0.82 ADORA2A (0.46) ADORA2AADORA1ADORA2BADORA3GRIA1
SCHEMBL20600736 0.82 ADORA2A (0.46) ADORA2AADORA1ADORA3GRIA1PDE4D
SCHEMBL20600615 0.82 GRIA1 (0.50) TGFBR1ADORA2AADORA1ADORA2BDYRK1A
SCHEMBL20600659 0.82 ADORA2A (0.45) ADORA2AADORA1ADORA2BADORA3GRIA1
SCHEMBL20600512 0.82 TGFBR1 (0.45) TGFBR1ADORA2AADORA1ADORA2BRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 TGFBR1 1069/4885ADORA2A 1/4885ADORA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.